TABLE 4.
Analysis of the ACTG175 trial data
| Zidovudine | Zidovudine plus | Difference | |||||
|---|---|---|---|---|---|---|---|
| (n = 197) | Didanosine (n = 185) | ||||||
| Method | RMST | SE | RMST | SE | RMST (95% CI) | SE | p-Value |
| Primary and sensitivity analysis with wild bootstrap | |||||||
| δ = 1 | 22.10 | 0.28 | 23.04 | 0.22 | 0.92 (0.15, 1.68) | 0.39 | 0.019 |
| δ = 2 | 22.10 | 0.28 | 23.00 | 0.23 | 0.88 (0.11, 1.64) | 0.39 | 0.024 |
| δ = 3 | 22.10 | 0.28 | 22.97 | 0.23 | 0.84 (0.18, 1.61) | 0.39 | 0.031 |
| δ = 4 | 22.10 | 0.28 | 22.93 | 0.23 | 0.81 (0.04, 1.58) | 0.39 | 0.038 |
| δ = 5 | 22.10 | 0.28 | 22.90 | 0.23 | 0.78 (0.02, 1.55) | 0.39 | 0.047 |
| Control-based | 22.12 | 0.31 | 23.00 | 0.23 | 0.88 (0.12, 1.65) | 0.39 | 0.023 |
| Primary and sensitivity analysis with Rubin’s combining rule | |||||||
| δ = 1 | 22.12 | 0.31 | 23.04 | 0.24 | 0.92 (0.14, 1.69) | 0.39 | 0.020 |
| δ = 2 | 22.12 | 0.31 | 23.00 | 0.25 | 0.88 (0.10, 1.67) | 0.40 | 0.027 |
| δ = 3 | 22.12 | 0.31 | 22.97 | 0.25 | 0.84 (0.06, 1.63) | 0.40 | 0.034 |
| δ = 4 | 22.12 | 0.31 | 22.93 | 0.26 | 0.81 (0.02, 1.60) | 0.40 | 0.043 |
| δ = 5 | 22.12 | 0.31 | 22.90 | 0.26 | 0.78 (−0.01, 1.59) | 0.40 | 0.054 |
| Control-based | 22.12 | 0.31 | 23.00 | 0.25 | 0.87 (0.08, 1.65) | 0.40 | 0.030 |
| (Tian et al., 2014) | 22.11 | 0.31 | 23.05 | 0.24 | 0.88 (0.11, 1.66) | 0.40 | 0.026 |
Note: In δ-adjusted sensitivity analysis, the value of δ applied to subjects who were nonadministrative censored in the Zidovudine plus Didanosine group.